Wednesday, February 6, 2019

Researchers at the University of Waterloo have developed a new way to prevent and treat Chlamydia, the most common sexually transmitted bacterial infection in the world. 

The new treatment differs from the traditional anti-biotic treatment as it is a type of gene therapy that is delivered via nanotechnology and is showing a 65 per cent success rate in preventing chlamydia infection on a single dose.

“As antibiotic resistance continues to develop, people may experience Chlamydia infections that cannot be treated through conventional means, which is causing increasing public health challenges,” said Emmanuel Ho, a professor at Waterloo’s School of Pharmacy. “If left untreated or if treatment takes an extended period of time it can lead to infertility and other reproductive issues so finding new ways to treat this common infection is important.

The new treatment created in Ho’s lab targets Chlamydia infection by preventing the majority of bacteria from entering cells in the genital tract and destroying any bacteria that is able to penetrate a cell wall.  The team was able to achieve this by using a small interfering ribonucleic acid (siRNA) to target a specific gene called PDGFR-beta in the female reproductive tract, which creates a protein that binds to Chlamydia bacteria.

Full Story: [Waterloo News]

  1. 2021 (3)
    1. August (2)
    2. June (1)
  2. 2020 (9)
    1. November (1)
    2. October (2)
    3. September (2)
    4. June (1)
    5. April (1)
    6. March (2)
  3. 2019 (11)
    1. November (2)
    2. October (3)
    3. July (1)
    4. March (1)
    5. February (4)
  4. 2018 (51)
  5. 2017 (45)
  6. 2016 (25)
  7. 2015 (26)
  8. 2014 (6)
  9. 2013 (13)
  10. 2012 (6)